These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 37605218)

  • 1. Current approaches to develop "off-the-shelf" chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review.
    Aparicio C; Acebal C; González-Vallinas M
    Exp Hematol Oncol; 2023 Aug; 12(1):73. PubMed ID: 37605218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic "Off-the-Shelf" CAR T cells: Challenges and advances.
    Chen S; van den Brink MRM
    Best Pract Res Clin Haematol; 2024 Sep; 37(3):101566. PubMed ID: 39396256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The paths and challenges of "off-the-shelf" CAR-T cell therapy: An overview of clinical trials.
    Moradi V; Omidkhoda A; Ahmadbeigi N
    Biomed Pharmacother; 2023 Dec; 169():115888. PubMed ID: 37979380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review.
    Tang C; Zhang Y
    Pathol Res Pract; 2024 Oct; 262():155518. PubMed ID: 39146830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
    Rafei H; Daher M; Rezvani K
    Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy.
    Lv Z; Luo F; Chu Y
    Front Immunol; 2023; 14():1199145. PubMed ID: 37554322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic chimeric antigen receptor T cells for children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Locatelli F; Del Bufalo F; Quintarelli C
    Haematologica; 2024 Jun; 109(6):1689-1699. PubMed ID: 38832424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Better by design: What to expect from novel CAR-engineered cell therapies?
    Luginbuehl V; Abraham E; Kovar K; Flaaten R; Müller AMS
    Biotechnol Adv; 2022 Sep; 58():107917. PubMed ID: 35149146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
    Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor T Cells: The Intersection of Stem Cells and Immunotherapy.
    Lahimchi MR; Maroufi F; Maali A
    Cell Reprogram; 2023 Oct; 25(5):195-211. PubMed ID: 37782910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma.
    Martínez Bedoya D; Dutoit V; Migliorini D
    Front Immunol; 2021; 12():640082. PubMed ID: 33746981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities.
    Vasic D; Lee JB; Leung Y; Khatri I; Na Y; Abate-Daga D; Zhang L
    Sci Immunol; 2022 Apr; 7(70):eabl3642. PubMed ID: 35452255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells.
    Klaihmon P; Luanpitpong S; Kang X; Issaragrisil S
    Cancer Cell Int; 2023 Nov; 23(1):297. PubMed ID: 38012684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Stem Cell-Derived Immune Cells for Off-the-Shelf Cancer Immunotherapies.
    Li YR; Dunn ZS; Zhou Y; Lee D; Yang L
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies.
    Dhakal B; Chhabra S; Savani BN; Hamadani M
    Br J Haematol; 2022 Apr; 197(1):28-40. PubMed ID: 34671973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
    Marcus A; Eshhar Z
    Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells.
    Aparicio C; Belver M; Enríquez L; Espeso F; Núñez L; Sánchez A; de la Fuente MÁ; González-Vallinas M
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.